December 9, 2019

TFF Pharmaceuticals Reports Third Quarter Results and Provides Business Update

November 25, 2019

TFF Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Voriconazole Inhalation Powder, to Treat Invasive Pulmonary Aspergillosis (IPA)

November 19, 2019

TFF Pharmaceuticals Selects LaVoieHealthScience as Investor Relations and Corporate Communications Partner

November 18, 2019

TFF Pharmaceuticals to Ring NASDAQ Stock Market Opening Bell on Wednesday, November 20, 2019

October 24, 2019

TFF Pharmaceuticals Prices $22 Million Public Offering of Common Stock

May 30, 2019

TFF Pharmaceuticals Raises $8.17 Million and Expands Leadership Team with New CFO and Director Appointments

September 27, 2018

TFF Pharmaceuticals Receives Notice of Intention to Grant European Patent for Its Thin Film Freezing Process, Providing IP Protection in Europe until 2028

July 11, 2018

TFF Pharmaceuticals Receives Notice of Allowance for New Foundational Patent Broadly Covering Novel Inhaled Dry Powder Drug Delivery Platform

May 8, 2018

TFF Pharmaceuticals Announces Appointment of Glenn Mattes as New Chief Executive Officer

May 3, 2018

Biopharm Startup TFF Pharmaceuticals Raises $14M for Breakthrough Dry Powder Inhalation Platform